Comment on: "Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of an NICE Single Technology Appraisal"
- PMID: 28390016
- DOI: 10.1007/s40273-017-0502-8
Comment on: "Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of an NICE Single Technology Appraisal"
Comment in
-
Response to Letter to the Editor Regarding "Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal".Pharmacoeconomics. 2017 Jun;35(6):665-667. doi: 10.1007/s40273-017-0507-3. Pharmacoeconomics. 2017. PMID: 28391508 No abstract available.
Comment on
-
Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of an NICE Single Technology Appraisal.Pharmacoeconomics. 2017 Feb;35(2):191-202. doi: 10.1007/s40273-016-0445-5. Pharmacoeconomics. 2017. PMID: 27566699 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
